Gurinderpal Doad
YOU?
Author Swipe
View article: Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)
Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies) Open
Despite current guidelines, over half of patients started selexipag almost 3 years after diagnosis, and 38% were already intermediate-high or high risk of 1-year mortality. Lower hospitalisation rates and better survival were observed for …
View article: Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity Open
Introduction Racial/ethnic minority populations in the US have a high burden of pulmonary arterial hypertension (PAH). Objective To evaluate demographics, disease characteristics, prescribing patterns, hospitalization, and survival in raci…
The Role of Telehealth in PAH Management: Benefits, Barriers, and Solutions Open
Telehealth utilization increased during the coronavirus disease‐2019 (COVID‐19) pandemic, which encouraged remote patient management. The identification of optimal strategies to enhance telehealth and address barriers to its use for patien…
Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review Open
Given differences in trial- and real-world outcomes, number of prior therapies, and dosing, personalizing the choice of oral PPA is critical to maximizing the benefit for individual patients.
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States Open
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited …